BACKGROUND: The short- and mid-term outcomes of the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES) in real-world patients had been reported previously, but the long-term performance remained unclear. The objective of this analysis was to evaluate the long-term safety and efficacy of the second-generation CoCr-SES from the FOCUS registry. METHODS: The FOCUS registry (ClinicalTrials.gov Identifier: NCT00868829) enrolled all-comers eligible to receive Firebird-2 CoCr-SES. Follow-up was continued to 3 years to evaluate long-term safety and effectiveness of the second-generation CoCr-SES in real-world practice. Results of the extended-use group and standard-use group are compared to explore performance of CoCr-SES in more severe patients with more complex lesions. RESULTS: The rate of 3-year MACE was 7.37%, consisting of 84 cases (1.78%) of cardiac death, 166 cases (3.52%) of MI and 98 cases (2.08%) of TVR. ARC definite/probable stent thrombosis happened in 34 (0.72%) patients, only 3 new cases (<0.1%) of very late stent thrombosis was reported in the third year. Meanwhile, the difference of MACE (7.77% vs. 6.06%; P=0.058), TLF (4.71% vs. 3.49%; P=0.085) and ARC definite/probable stent thrombosis (0.83% vs. 0.37%; P=0.116) between extended-use group and standard-use group showed no significance. CONCLUSIONS: The second-generation CoCr-SES was associated with continued low rates of 3-year MACE, TLF and stent thrombosis in a broad spectrum of patients.
BACKGROUND: The short- and mid-term outcomes of the second-generation cobalt-chromium sirolimus-eluting stent (CoCr-SES) in real-world patients had been reported previously, but the long-term performance remained unclear. The objective of this analysis was to evaluate the long-term safety and efficacy of the second-generation CoCr-SES from the FOCUS registry. METHODS: The FOCUS registry (ClinicalTrials.gov Identifier: NCT00868829) enrolled all-comers eligible to receive Firebird-2 CoCr-SES. Follow-up was continued to 3 years to evaluate long-term safety and effectiveness of the second-generation CoCr-SES in real-world practice. Results of the extended-use group and standard-use group are compared to explore performance of CoCr-SES in more severe patients with more complex lesions. RESULTS: The rate of 3-year MACE was 7.37%, consisting of 84 cases (1.78%) of cardiac death, 166 cases (3.52%) of MI and 98 cases (2.08%) of TVR. ARC definite/probable stent thrombosis happened in 34 (0.72%) patients, only 3 new cases (<0.1%) of very late stent thrombosis was reported in the third year. Meanwhile, the difference of MACE (7.77% vs. 6.06%; P=0.058), TLF (4.71% vs. 3.49%; P=0.085) and ARC definite/probable stent thrombosis (0.83% vs. 0.37%; P=0.116) between extended-use group and standard-use group showed no significance. CONCLUSIONS: The second-generation CoCr-SES was associated with continued low rates of 3-year MACE, TLF and stent thrombosis in a broad spectrum of patients.
Authors: Caroline Franck; Mark J Eisenberg; Tara Dourian; Sonia M Grandi; Kristian B Filion Journal: Int J Cardiol Date: 2014-11-05 Impact factor: 4.164
Authors: Gregg W Stone; Ali Rizvi; William Newman; Kourosh Mastali; John C Wang; Ronald Caputo; Julie Doostzadeh; Sherry Cao; Charles A Simonton; Krishnankutty Sudhir; Alexandra J Lansky; Donald E Cutlip; Dean J Kereiakes Journal: N Engl J Med Date: 2010-05-06 Impact factor: 91.245
Authors: Lorenz Räber; Peter Jüni; Eveline Nüesch; Bindu Kalesan; Peter Wenaweser; Aris Moschovitis; Ahmed A Khattab; Maryam Bahlo; Mario Togni; Stéphane Cook; Rolf Vogel; Christian Seiler; Bernhard Meier; Stephan Windecker Journal: J Am Coll Cardiol Date: 2011-05-24 Impact factor: 24.094
Authors: Nicholas N Hanna; Michael A Gaglia; Rebecca Torguson; Itsik Ben-Dor; Manuel A Gonzalez; Sara D Collins; Asmir I Syed; Gabriel Maluenda; Kimberly Kaneshige; Zhenyi Xue; Lowell F Satler; Kenneth M Kent; William O Suddath; Augusto D Pichard; Ron Waksman Journal: Am J Cardiol Date: 2010-08-15 Impact factor: 2.778
Authors: Eric L Eisenstein; Martin B Leon; David E Kandzari; Laura Mauri; Rex Edwards; David F Kong; Patricia A Cowper; Kevin J Anstrom Journal: JACC Cardiovasc Interv Date: 2009-12 Impact factor: 11.195
Authors: Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell Journal: N Engl J Med Date: 2004-01-15 Impact factor: 91.245